A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

PHASE3CompletedINTERVENTIONAL
Enrollment

181

Participants

Timeline

Start Date

June 18, 2020

Primary Completion Date

November 29, 2021

Study Completion Date

January 12, 2022

Conditions
Eosinophilic GastritisEosinophilic Duodenitis
Interventions
DRUG

lirentelimab (AK002)

Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.

OTHER

Placebo

Placebo

Trial Locations (60)

10029

Allakos Investigational Site, New York

11021

Allakos Investigational Site, Great Neck

17822

Allakos Investigational Site, Danville

19104

Allakos Investigational Site, Philadelphia

20815

Allakos Investigational Site, Chevy Chase

22031

Allakos Investigational Site, Fairfax

27599

Allakos Investigational Site, Chapel Hill

27710

Allakos Investigational Site, Durham

27804

Allakos Investigational Site, Rocky Mount

28210

Allakos Investigational Site, Charlotte

30342

Allakos Investigational Site, Atlanta

32132

Allakos Investigational Site, Edgewater

32256

Allakos Investigational Site, Jacksonville

33176

Allakos Investigational Site, Miami

33511

Allakos Investigational Site, Brandon

34653

Allakos Investigational Site, New Port Richey

35209

Allakos Investigational Site, Birmingham

37212

Allakos Investigational Site, Nashville

37343

Allakos Investigational Site, Hixson

37421

Allakos Investigational Site, Chattanooga

37663

Allakos Investigational Site, Kingsport

38801

Allakos Investigational Site, Huntsville

44060

Allakos Investigational Site, Mentor

44106

Allakos Investigational Site, Cleveland

45229

Allakos Investigational Site, Cincinnati

45231

Allakos Investigational Site, Cincinnati

45415

Allakos Investigational Site, Dayton

48109

Allakos Investigational Site, Ann Arbor

55905

Allakos Investigational Site, Rochester

60611

Allakos Investigational Site, Chicago

64108

Allakos Investigational Site, Kansas City

70526

Allakos Investigational Site, Crowley

72205

Allakos Investigational Site, Little Rock

73112

Allakos Investigational Site, Oklahoma City

77070

Allakos Investigational Site, Houston

78704

Allakos Investigational Site, Austin

80045

Allakos Investigational Site, Aurora

80907

Allakos Investigational Site, Colorado Springs

84065

Allakos Investigational Site, Riverton

84092

Allakos Investigational Site, Sandy City

84132

Allakos Investigational Site, Salt Lake City

84405

Allakos Investigational Site, Ogden

85021

Allakos Investigational Site, Phoenix

85234

Allakos Investigational Site, Gilbert

85259

Allakos Investigational Site, Scottsdale

89106

Allakos Investigational Site, Las Vegas

89511

Allakos Investigational Site, Reno

90404

Allakos Investigational Site, Santa Monica

91910

Allakos Investigational Site, Chula Vista

92037

Allakos Investigational Site, La Jolla

92563

Allakos Investigational Site, Murrieta

92780

Allakos Investigational Site, Tustin

93003

Allakos Investigational Site, Ventura

94598

Allakos Investigational Site, Walnut Creek

94612

Allakos Investigational Site, Oakland

99202

Allakos Investigational Site, Spokane

06010

Allakos Investigational Site, Bristol

02111

Allakos Investigational Site, Boston

02115

Allakos Investigational Site, Boston

02215

Allakos Investigational Site, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allakos Inc.

INDUSTRY

NCT04322604 - A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) | Biotech Hunter | Biotech Hunter